These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 15931272

  • 21. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
    Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group.
    J Urol; 2004 Nov; 172(5 Pt 1):1865-70. PubMed ID: 15540740
    [Abstract] [Full Text] [Related]

  • 22. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
    Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S.
    Eur Urol; 2007 Jul; 52(1):106-14. PubMed ID: 17270340
    [Abstract] [Full Text] [Related]

  • 23. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.
    Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S, Kanetake H, Naito S, Sumiyoshi Y, Takimoto Y, Terai A, Yoshida H, Ohashi Y.
    Prostate Cancer Prostatic Dis; 2007 Jul; 10(2):194-201. PubMed ID: 17199134
    [Abstract] [Full Text] [Related]

  • 24. Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.
    See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T.
    Eur Urol; 2003 Nov; 44(5):512-7; discussion 517-8. PubMed ID: 14572747
    [Abstract] [Full Text] [Related]

  • 25. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
    Thomsen FB, Brasso K, Christensen IJ, Johansson JE, Angelsen A, Tammela TL, Iversen P, Scandinavian Prostate Cancer Group.
    Eur J Cancer; 2015 Jul; 51(10):1283-92. PubMed ID: 25892647
    [Abstract] [Full Text] [Related]

  • 26. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G, Longo F.
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract] [Full Text] [Related]

  • 29. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
    Wirth M, Tyrrell C, Wallace M, Delaere KP, Sánchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes CF, Borchers TM, Morris T, Stone A.
    Urology; 2001 Aug; 58(2):146-51. PubMed ID: 11489683
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
    Van Poppel H, Tyrrell CJ, Haustermans K, Cangh PV, Keuppens F, Colombeau P, Morris T, Garside L.
    Eur Urol; 2005 May; 47(5):587-92. PubMed ID: 15826748
    [Abstract] [Full Text] [Related]

  • 32. [Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer].
    Kariakin OB, Sviridova TV, Tsodikova LB, Grishin GN, Sergeeva TN, Perekhrest MA, Donichkina EA.
    Urologiia; 2001 May; (4):26-9. PubMed ID: 11569230
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
    Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K, Scandinavian Prostatic Cancer Group.
    J Urol; 2004 Nov; 172(5 Pt 1):1871-6. PubMed ID: 15540741
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Bicalutamide: in early-stage prostate cancer.
    Carswell CI, Figgitt DP.
    Drugs; 2002 Nov; 62(17):2471-79; discussion 2480-1. PubMed ID: 12421104
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.